More Favorable Metabolic Impact of Three-Times-Weekly versus Daily Growth Hormone Treatment in Naïve GH-Deficient Children
Table 4
Change (delta) in clinical and metabolic parameters from baseline to 12 months of GH treatment of patients grouped according to the GH treatment regimen.
7 doses per week (group A) 16 patients
3 doses per week (group B) 16 patients
Mean ± SD
Mean ± SD
Delta height (SD)
0.5 ± 0.3
0.5 ± 0.2
0.926
Delta BMI (SD)
0.03 ± 0.6
−0.4 ± 0.6
0.109
Delta waist circumference (cm)
1.4 ± 4.4
1.4 ± 4.8
0.223
Delta growth velocity (SD)
5.2 ± 1.7
6.3 ± 2.7
0.945
Delta IGF-I (μg/L)
220.5 ± 112.7
204.8 ± 70.9
0.210
Delta fasting glucose (mmol/L)
0.78 ± 0.76
0.34 ± 0.32
0.175
Delta fasting insulin (IU/mL)
6.3 ± 4.2
2.9 ± 3.4
0.043
Delta HbA1c (%)
0.07 ± 0.1
−0.05 ± 0.1
0.078
Delta Homa-IR
1.46 ± 0.99
0.63 ± 0.70
0.032
Delta ISI-Matsuda
−1.06 ± 0.43
−0.21 ± 0.19
<0.001
Delta DIo
−1.31 ± 0.97
−0.37 ± 0.34
0.001
Delta total cholesterol (mmol/L)
0.06 ± 0.01
0.08 ± 0.05
0.941
Delta HDL cholesterol (mmol/L)
0.04 ± 0.03
−0.12 ± 0.04
0.209
Delta LDL cholesterol (mmol/L)
0.01 ± 0.01
0.15 ± 0.04
0.498
Delta triglycerides (mmol/L)
0.04 ± 0.03
0.13 ± 0.05
0.392
BMI: body mass index; DIo: oral disposition index.
